An interventional study of Stereotactic Radiotherapy in Metastatic Cancer, sponsored by Elsan. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Elsan · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 542 studies in Neoplasm Metastasis with a site in France — 93 open to participants now, 165 under way, 50 of them phase 3. Neoplasm Metastasis · France.
Among the 542 studies in Neoplasm Metastasis with a site in France, this one is the 396th largest by planned enrollment of the 477 interventional ones that give a count, is one of 18 that started in 2026, is one of 62 with no phase, reaches primary completion later than 74 of the 164 other live ones, and was the 482nd registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →93 of the 542 studies in Neoplasm Metastasis with a site in France are open now. Recruiting first, the newest first:
UNICANCER · Sites in France
Ages 12+
Centre Georges Francois Leclerc · Sites in France
Ages 18+
Mark C Burgmans, MD PhD · Sites in France, Netherlands
Ages 18+
AstraZeneca · Sites in France, United States, Germany and 6 more countries
Ages 18–130
Regeneron Pharmaceuticals · Sites in France, United States, Australia and 3 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
542 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 123 · Phase 2 218 · Phase 3 138 · Phase 4 6
First in 1990; this study’s year is marked. 18 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 133 across the 477 interventional studies, 120 across the 59 observational. Of the 338 that completed or were terminated, 134 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
293 of 542 have an industry lead sponsor. The 10 most frequent:
Elsan is the lead sponsor of 68 studies on the registry; 35 are open to participants now.
Elsan has 1 study filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
42 of the studies in Neoplasm Metastasis with a site in France that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06103864Phase 3AstraZenecaA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | 2027-07-28 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT01442246Phase 3UNICANCEREvaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients. | 2027-09 |
Add all 42 to your calendar (.ics) → With an account.
Among the 542 studies in Neoplasm Metastasis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims at enrolling patients with solid tumors at metastatic stage, considered long responders to immunotherapy (> 6 months) and displaying disease progression.
In this study, the investigator wants to evaluate specific modalities of stereotactic radiotherapy, with 3 sessions, each of 8 Gy, lasting 20 minutes and spaced 72 hours apart (Day 1, Day 4, Day 7). The radiotherapy device itself is not the subject of this study and will be used in accordance with its CE mark and indications.
The objective of the study is to assess the ability of stereotactic radiotherapy to restore the lost efficacy of immunotherapy. In particular, the abscopal effect will be assessed, i.e. the action of irradiating a particular target lesion and observing an effect on other distant metastases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will perform stereotactic radiotherapy with 3 sessions (8 Gy) during 20 minutes each and with 72 hours in-between, alongside anti-PD1 immunotherapy.
Radiation: Stereotactic Radiotherapy
Patients will perform stereotactic radiotherapy with 3 sessions (8 Gy) during 20 minutes each and with 72 hours in-between. Patients enrolled in the study would not have received this stereotactic radiotherapy outside the study, that is why this procedure is additional (compared to Standard of care) and considered as burdensome (as this is radiation). Before performing the stereotactic radiotherapy, patients will do a radiotherapy CT scanner (no injected) in order to prepare precisely the radiotherapy (treatment plan).
Objective Response Rate according to iRECIST criteria at 3 months after stereotactic radiotherapy in patients with confirmed progression after initial response to immunotherapy.
Assessment of Objective Response Rate (Complete Response and Partial Response with iRECIST criteria) according to a centralised independent reading.
Time frame: At 3 months after stereotactic radiotherapy
Objective Response Rate according to RECIST 1.1 criteria at 3 months after stereotactic RT in patients with progression after initial response to immunotherapy.
Assessment of Objective Response Rate (Complete Response and Partial Response with RECIST 1.1 criteria) according to a centralised independent reading.
Time frame: At 3 months after stereotactic radiotherapy
Objective Response Rate according to iRECIST criteria up to 12 months after stereotactic radiotherapy in patients with confirmed progression after initial response to immunotherapy.
Time frame: Up to 12 months after stereotactic radiotherapy
Objective Response Rate according to RECIST 1.1 criteria up to 12 months after stereotactic radiotherapy in patients with confirmed progression after initial response to immunotherapy.
Time frame: Up to 12 months after stereotactic radiotherapy
Duration until new systemic treatment start.
Duration (in days) before introduction of a new systemic treatment.
Time frame: Up to 12 months after stereotactic radiotherapy
Incidence of Adverse Events (safety)
Collection of adverse events (AEs) up to 12 months after radiotherapy.
Time frame: Up to 12 months after stereotactic radiotherapy
Progression-Free Survival
Time frame: Up to 12 months after stereotactic radiotherapy
Overall Survival
Time frame: Up to 12 months after stereotactic radiotherapy
Objective Response Rate according to iRECIST criteria on the irradiated lesion only.
Time frame: Up to 12 months after stereotactic radiotherapy
Objective Response Rate according to RECIST 1.1 criteria on the irradiated lesion only.
Time frame: Up to 12 months after stereotactic radiotherapy
Objective Response Rate according to iRECIST criteria on all untreated lesion(s) (abscopal effect).
Time frame: Up to 12 months after stereotactic radiotherapy
Objective Response Rate according to RECIST 1.1 criteria on all untreated lesion(s) (abscopal effect).
Time frame: Up to 12 months after stereotactic radiotherapy
Objective Response Rate according to iRECIST criteria on each untreated lesion taken independently from others (abscopal effect).
Time frame: Up to 12 months after stereotactic radiotherapy
Objective Response Rate according to RECIST 1.1 criteria on each untreated lesion taken independently from others (abscopal effect).
Time frame: Up to 12 months after stereotactic radiotherapy
Started Jan 2026 (actual). Primary completion is estimated for Apr 2027, 15 months after the start.
Of 295 non-industry interventional studies with no phase under Neoplasm Metastasis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 93. This study's planned 15 months is below that.
Counting every sponsor, half of 320 studies reached it within 54 months; a quarter within 28 and three quarters within 91.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Elsan